SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001564590-17-009390
Filing Date
2017-05-08
Accepted
2017-05-08 16:15:37
Documents
46
Period of Report
2017-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q aimt-10q_20170331.htm 10-Q 1588163
2 EX-10.1 aimt-ex101_43.htm EX-10.1 75941
3 EX-31.1 aimt-ex311_8.htm EX-31.1 19480
4 EX-31.2 aimt-ex312_6.htm EX-31.2 19456
5 EX-32.1 aimt-ex321_7.htm EX-32.1 16902
  Complete submission text file 0001564590-17-009390.txt   4917449

Data Files

Seq Description Document Type Size
6 XBRL INSTANCE DOCUMENT aimt-20170331.xml EX-101.INS 1071862
7 XBRL TAXONOMY EXTENSION SCHEMA aimt-20170331.xsd EX-101.SCH 25722
8 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE aimt-20170331_cal.xml EX-101.CAL 29296
9 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE aimt-20170331_def.xml EX-101.DEF 78292
10 XBRL TAXONOMY EXTENSION LABEL LINKBASE aimt-20170331_lab.xml EX-101.LAB 240342
11 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE aimt-20170331_pre.xml EX-101.PRE 175989
Mailing Address 8000 MARINA BOULEVARD SUITE 300 BRISBANE CA 94005-1884
Business Address 8000 MARINA BOULEVARD SUITE 300 BRISBANE CA 94005-1884 (650) 614-5220
Aimmune Therapeutics, Inc. (Filer) CIK: 0001631650 (see all company filings)

IRS No.: 452748244 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37519 | Film No.: 17822411
SIC: 2834 Pharmaceutical Preparations